

3: Ozaki T, Flege S, Liljenqvist U, Hillmann A, Delling G, Salzer-Kuntschik M, Jurgens H, Kotz R, Winkelmann W, Bielack SS. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer. 2002 Feb 15;94(4):1069-77. 
&&url PMID: 11920477  

4: Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP, Bruland OS. 
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002 Jan 1;20(1):189-96. 
&&url PMID: 11773169  

5: Ramamoorthy N, Saraswathy P, Das MK, Mehra KS, Ananthakrishnan M. 
Production logistics and radionuclidic purity aspects of 153Sm for radionuclide therapy. Nucl Med Commun. 2002 Jan;23(1):83-9. 
&&url PMID: 11748442  

6: Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Jurgens H, Schober O. 
High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin. 2001 Dec;40(6):215-20. 
&&url PMID: 11797510  

8: Thurman SA, Ramakrishna NR, DeWeese TL. 
Radiation therapy for the treatment of locally advanced and metastatic prostate cancer. Hematol Oncol Clin North Am. 2001 Jun;15(3):423-43. 
&&url PMID: 11525289  

9: Serafini AN. 
Therapy of metastatic bone pain. J Nucl Med. 2001 Jun;42(6):895-906. 
&&url PMID: 11390554  

11: Serafini AN. 
Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med. 2001 Mar;45(1):91-9. Review. 
&&url PMID: 11456381  


13: Brenner W, Kampen WU, Kampen AM, Henze E. 
Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med. 2001 Feb;42(2):230-6. 
&&url PMID: 11216521  


15: Silberstein EB, Eugene L, Saenger SR. 
Painful osteoblastic metastases: the role of nuclear medicine. Oncology (Huntingt). 2001 Feb;15(2):157-63; discussion 167-70, 174. Review. 
&&url PMID: 11252931  

20: Silberstein EB. 
Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol. 2000 Jul;10(3):240-9. Review. 
&&url PMID: 11034634  

21: Serafini AN. 
Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000 Jun 15;88(12 Suppl):2934-9. Review. 
&&url PMID: 10898337  

23: McEwan AJ. 
Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000 Apr;10(2):103-14. Review. 
&&url PMID: 10727599  

25: Klutmann S, Bohuslavizki KH. 
[Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP] MMW Fortschr Med. 1999 Nov 4;141(44):38-9. German. 
&&url PMID: 10912142  

26: Dickie GJ, Macfarlane D. 
Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol. 1999 Nov;43(4):476-9. 
&&url PMID: 10901963  

28: Papatheofanis FJ. 
Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy. J Nucl Med. 1999 Sep;40(9):1420-3. 
&&url PMID: 10492359  

29: Cameron PJ, Klemp PF, Martindale AA, Turner JH. 
Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy. Nucl Med Commun. 1999 Jul;20(7):609-15. 
&&url PMID: 10423762  

33: Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ. 
Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999 Jan;26(1):2-7. 
&&url PMID: 9933654  

34: Franzius C, Bielack S, Sciuk J, Vollet B, Jurgens H, Schober O. 
High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin. 1999;38(8):337-40. 
&&url PMID: 10615669  

35: van Rensburg AJ, Alberts AS, Louw WK. 
Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. J Nucl Med. 1998 Dec;39(12):2110-5. 
&&url PMID: 9867152  

36: Coleman RE. 
How can we improve the treatment of bone metastases further? Curr Opin Oncol. 1998 Aug;10 Suppl 1:S7-13. Review. 
&&url PMID: 9801853  

37: Lovera C, Massardo T, Galleguillos MC, Gonzalez P, Comparini B, Yanez M, Fodor M, Gil MC, Araya G, Tomicic M. 

[Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate] Rev Med Chil. 1998 Aug;126(8):963-71. Spanish. 
&&url PMID: 9830748  

38: Knapp FF Jr, Mirzadeh S, Beets AL, O'Doherty M, Blower PJ, Verdera ES, Gaudiano JS, Kropp J, Guhlke J, Palmedo H, Biersack HJ. 
Reactor-produced radioisotopes from ORNL for bone pain palliation. Appl Radiat Isot. 1998 Apr;49(4):309-15. 
&&url PMID: 9519440  

39: Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. 
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998 Apr;16(4):1574-81. 
&&url PMID: 9552068  

47: Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D.Related Articles 
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997 Sep;33(10):1583-91. 
&&url PMID: 9389919  

49: Alberts AS, Smit BJ, Louw WK, van Rensburg AJ, van Beek A, Kritzinger V, Nel JS. 
Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol. 1997 May;43(2):175-9. 
&&url PMID: 9192964  

50: McEwan AJ. 
Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med. 1997 Apr;27(2):165-82. Review. 
&&url PMID: 9144858  

51: Ben-Josef E, Porter AT. 
Radioisotopes in the treatment of bone metastases. Ann Med. 1997 Feb;29(1):31-5. Review. 
&&url PMID: 9073322  

53: Lewington VJ. 
Cancer therapy using bone-seeking isotopes. Phys Med Biol. 1996 Oct;41(10):2027-42. Review. 
&&url PMID: 8912378  

55: Atkins HL, Srivastava SC. 
Radiolabeled bone-seeking radiopharmaceuticals. Q J Nucl Med. 1996 Sep;40(3):285-9. Review. 
&&url PMID: 8961805  

56: Olea E, Gil MC, Tomicic M, Araya G, Chandia M, Quintana JC, Pinto L, Orellana P, Nagel J, Ortiz V. 
[Nationally produced 153SmEDTMP in the palliative treatment of metastatic bone cancer pain] Rev Med Chil. 1996 Jul;124(7):805-12. Spanish. 
&&url PMID: 9138368  

59: Bruland OS, Skretting A, Solheim OP, Aas M. 
Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol. 1996;35(3):381-4. 
&&url PMID: 8679270  

60: Deng H, Luo S, Tan T, Mo T, Liang Z, Pu M, Jiao J, Zhong S, Wang Q, Hu Y, et al. 
[153Sm-EDTMP for moderate and severe bone cancer pain] Hua Xi Yi Ke Da Xue Xue Bao. 1995 Dec;26(4):391-4. Chinese. 
&&url PMID: 8732058  

61: Robinson RG, Preston DF, Schiefelbein M, Baxter KG.Related Articles 
Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995 Aug 2;274(5):420-4. Review. 
&&url PMID: 7542352  

62: Deng H, Tan T, Mo T, Zhong S, Kuan A, Hu Y. 
[Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor] Hua Xi Yi Ke Da Xue Xue Bao. 1995 Jun;26(2):155-9. Chinese. 
&&url PMID: 7490021  

64: Serafini AN. 
Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1187-94. Review. 
&&url PMID: 7525518  

65: Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jakobsson M, Jurvelin J, Kairemo K, Kumpulainen E, Kulmala J, et al. 

Samarium-153-EDTMP in bone metastases. J Nucl Biol Med. 1994 Dec;38(4 Suppl 1):123-7. 
&&url PMID: 7543288  

66: Porter AT, Ben-Josef E, Davis L. 
Systemic administration of new therapeutic radioisotopes, including phosphorus, strontium, samarium, and rhenium. Curr Opin Oncol. 1994 Nov;6(6):607-10. Review. 
&&url PMID: 7827173  

67: Jiang CY, Zhu BL, Zhang YJ. 
[The value of Sm-153-EDTMP for treatment of metastatic bone pain and improving quality of life] Zhonghua Zhong Liu Za Zhi. 1994 Mar;16(2):118-21. Chinese. 
&&url PMID: 7523052  

68: Schott ME, Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Cheng R, Kruper WJ Jr, Fordyce W, Goeckeler W.Related Articles 
Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer. 1994 Feb 1;73(3 Suppl):993-8. 
&&url PMID: 8306291  

69: Porter AT, Davis LP. 
Systemic radionuclide therapy of bone metastases with strontium-89. Oncology (Huntingt). 1994 Feb;8(2):93-6; discussion 96, 99-101. 
&&url PMID: 8167090  

72: Bayouth JE, Macey DJ, Kasi LP, Fossella FV. 

Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994 Jan;35(1):63-9. 
&&url PMID: 7505819  

73: Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR.Related Articles 
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993 Nov;34(11):1839-44. 
&&url PMID: 8229221  

75: Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F, et al.Related Articles 
Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993 Jul;34(7):1031-6. 
&&url PMID: 7686217  

76: Goeckeler WF, Stoneburner LK, Kasi LP, Fossella FV, Price DR, Fordyce WA. 
Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. Nucl Med Biol. 1993 Jul;20(5):657-61. 
&&url PMID: 8358352  

77: Holmes RA. 
Radiopharmaceuticals in clinical trials. Semin Oncol. 1993 Jun;20(3 Suppl 2):22-6. Review. 
&&url PMID: 7684861  

79: Lewington VJ. 
Targeted radionuclide therapy for bone metastases. Eur J Nucl Med. 1993 Jan;20(1):66-74. Review. 
&&url PMID: 7678397  

81: Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A.Related Articles 
Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992 Aug;33(8):1451-8. 
&&url PMID: 1378887  

82: Sandeman TF, Budd RS, Martin JJ. 
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin Oncol (R Coll Radiol). 1992 May;4(3):160-4. 
&&url PMID: 1375094  

84: Robinson RG, Preston DF, Spicer JA, Baxter KG. 
Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med. 1992 Jan;22(1):28-32. Review. 
&&url PMID: 1589803  

85: Holmes RA. 
[153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992 Jan;22(1):41-5. Review. 
&&url PMID: 1589805  

88: Turner JH, Claringbold PG. 
A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;27(9):1084-6. 
&&url PMID: 1720321  

95: Goodman JH, Gahbauer RA, Kanellitsas C, Clendenon NR, Laster BH, Fairchild RG. 
Theoretical basis and clinical methodology for stereotactic interstitial brain tumor irradiation using iododeoxyuridine as a radiation sensitizer and 145Sm as a brachytherapy source. Stereotact Funct Neurosurg. 1990;54-55:531-4. 
&&url PMID: 1964244  

96: Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. 

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol. 1989 Dec;7(12):1926-31. 
&&url PMID: 2585026  

97: Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, Ketring AR. 
Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989 Nov;30(11):1814-8. 
&&url PMID: 2478681  

99: Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG. 
Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15(12):784-95. 
&&url PMID: 2483138  

100: Fairchild RG, Kalef-Ezra J, Packer S, Wielopolski L, Laster BH, Robertson JS, Mausner L, Kanellitsas C. 
Samarium-145: a new brachytherapy source. Phys Med Biol. 1987 Jul;32(7):847-58. 
&&url PMID: 3615583  

101: Logan KW, Volkert WA, Holmes RA. 
Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. J Nucl Med. 1987 Apr;28(4):505-9. 
&&url PMID: 3572536  

102: Ketring AR. 
153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B. 1987;14(3):223-32. 
&&url PMID: 3117736  

103: Goeckeler WF, Troutner DE, Volkert WA, Edwards B, Simon J, Wilson D. 
153Sm radiotherapeutic bone agents. Int J Rad Appl Instrum B. 1986;13(4):479-82. 
&&url PMID: 3793505  

107: Muller WA, Schaffer EH, Linzner U. 
Studies on incorporated short-lived beta-emitters with regard to the induction of late effects. Radiat Environ Biophys. 1980;18(1):1-11. 
&&url PMID: 6934560  

108: Shah Syed GM, Maken RN, Muzzaffar N, Shah MA, Rana F. 
Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nucl Med Commun 1999 Aug;20(8):697-702 
&&url PMID: 10451877  

109: Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L. 
A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer. 2002 Mar 15;94(6):1654-60. 
&&url PMID: 11920525  

109: Windsor PM. 
Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin Oncol (R Coll Radiol). 2001;13(3):219-27. 
&&url PMID: 11527299  

110: Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. 
A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001 Jul;28(7):788-98. 
&&url PMID: 11504074  

117: Blake GM, Zivanovic MA, McEwan AJ, Condon BR, Ackery DM. 
Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma. Br J Radiol 1987 Mar;60(711):253-9 

118: Giammarile F, Mognetti T, Resche I. 
Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q J Nucl Med. 2001 Mar;45(1):78-83. Review. 
&&url PMID: 11456379  

119: Fuster D, Herranz R, Alcover J, Mateos JJ, Martin F, Vidal-Sicart S, Pons F. 
[Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm] Rev Esp Med Nucl. 2000 Aug;19(4):270-4. Spanish. 
&&url PMID: 11062097  

120: Silberstein EB. 
Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol 2000 Jul;10(3):240-9 
&&url PMID: 11034634  

121: Kossman SE, Weiss MA. 
Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer 2000 Feb 1;88(3):620-4 

122: Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NS, Russell JM, Yardley J. 
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994 Apr;31(1):33-40 

123: Dearnaley DP, Bayly RJ, A'Hern RP, Gadd J, Zivanovic MM, Lewington VJ. 
Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? Oncol (R Coll Radiol) 1992 Mar;4(2):101-7 
&&url PMID: 1372817  

124: Kothari K, Samuel G, Banerjee S, Unni PR, Sarma HD, Chaudhari PR, Unnikrishnan TP, Pillai MR. 
186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation. Nucl Med Biol 2001 Aug;28(6):709-17 
&&url PMID: 11518653  

125: Berk L. 
Prospective trials for the radiotherapeutic treatment of bone metastases. Am J Hosp Palliat Care 1995 Jul-Aug;12(4):24-8 
&&url PMID: 7543272  indexed for MEDLINE 

126: Powsner RA, Zietman AL, Foss FM. 
Bone marrow suppression after strontium-89 therapy and local radiation therapy in patients with diffuse marrow involvement. Clin Nucl Med 1997 Mar;22(3):147-50 
&&url PMID: 9067666  

